J Natl Cancer Inst 93 (9): 684-90, 2001.[PUBMED Abstract] Stewart HJ, Prescott RJ, Forrest AP: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.
J Natl Cancer Inst 93 (6): 456-62, 2001.[PUBMED Abstract] Tormey DC, Gray R, Falkson HC: Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer.
Eastern Cooperative Oncology Group.
J Natl Cancer Inst 88 (24): 1828-33, 1996.[PUBMED Abstract] Davies C, Pan H, Godwin J, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.